Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Silence Therapeutics Plc ADR (SLN)

Silence Therapeutics Plc ADR (SLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Silence Therapeutics Plc ADR 72 HAMMERSMITH ROAD LONDON X0 W14 8TH GBR

www.silence-therapeutics.com P: 44-0-20-3457-6900

Description:

Silence Therapeutics plc focuses on the discovery, development and delivery of novel RNA therapeutics in hematology, cardiovascular and other rare and metabolic indications. The Company's product candidate consist SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein and SLN500 for the treatment of complement-mediated diseases which are in clinical stage. Silence Therapeutics plc is based in London, the United Kingdom.

Key Statistics

Overview:

Market Capitalization, $K 618,612
Enterprise Value, $K 551,402
Shares Outstanding, K 29,928
Annual Sales, $ 31,560 K
Annual Net Income, $ -53,820 K
Last Quarter Sales, $ 15,730 K
Last Quarter Net Income, $ -2,380 K
EBIT, $ -52,220 K
EBITDA, $ -51,600 K
60-Month Beta 1.30
% of Insider Shareholders 2.95%
% of Institutional Shareholders 98.73%
Float, K 29,045
% Float 97.05%
Short Volume Ratio 0.24

Growth:

1-Year Return 285.25%
3-Year Return -14.39%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.05 on 05/16/24
Next Earnings Date 08/21/24
Earnings Per Share ttm -1.16
EPS Growth vs. Prev Qtr 89.36%
EPS Growth vs. Prev Year 85.71%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

SLN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -79.90%
Return-on-Assets % -29.00%
Profit Margin % -170.53%
Debt/Equity 0.00
Price/Sales 19.26
Price/Cash Flow N/A
Price/Book 3.87
Book Value/Share 5.25
Interest Coverage -22.35
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar